Tectonic therapeutic announces positive interim data from phase 1b trial for tx45 in patients with group 2 pulmonary hypertension in hfpef

Watertown, mass., jan. 30, 2025 (globe newswire) -- tectonic therapeutic, inc. (nasdaq: tecx) (“tectonic”), today announced positive interim data from the phase 1b acute hemodynamic clinical trial of its lead product candidate, tx45, a long-acting, fc-relaxin fusion protein. the interim data showed that a single intravenous dose of tx45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with group 2 pulmonary hypertension in heart failure with preserved ejection fraction (“ph-hfpef”). in the trial, tx45 was well tolerated in patients with ph-hfpef with no serious or severe adverse events.
TECX Ratings Summary
TECX Quant Ranking